Published in Am J Trop Med Hyg on November 01, 1989
Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus. J Virol (1991) 1.83
The relationship of Plasmodium falciparum humeral immunity with HIV-1 immunosuppression and treatment efficacy in Zambia. Malar J (2009) 0.96
Impact of human immunodeficiency virus infection in pregnant women on variant-specific immunity to malaria. Clin Vaccine Immunol (2008) 0.86
Effects of Maternal Plasmodium falciparum Malaria and HIV infection on Birth Weight in Southeastern Nigeria. Mcgill J Med (2009) 0.81
Serologic responses to recombinant Pneumocystis jirovecii major surface glycoprotein among Ugandan patients with respiratory symptoms. PLoS One (2012) 0.80
Association of HIV-Induced Immunosuppression and Clinical Malaria in Nigerian Adults. Afr J Infect Dis (2012) 0.78
Prevalence and correlates of insecticide-treated bednet use among HIV-1-infected adults in Kenya. AIDS Care (2012) 0.75
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet (2001) 13.32
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet (1999) 10.28
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med (1997) 8.43
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science (1999) 8.11
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA (2000) 7.65
HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet (1997) 7.52
Direct detection of Chlamydia trachomatis in urine specimens from symptomatic and asymptomatic men by using a rapid polymerase chain reaction assay. J Clin Microbiol (1993) 6.21
AIDS in Africa: an epidemiologic paradigm. Science (1986) 5.88
Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA (2001) 5.52
Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health (1996) 5.45
Sex differences in HIV-1 viral load and progression to AIDS. Lancet (1998) 5.24
Ligase chain reaction to detect Chlamydia trachomatis infection of the cervix. J Clin Microbiol (1994) 5.15
Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. Rakai Project Team. AIDS (2000) 5.14
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys (2000) 5.06
Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med (1999) 5.05
Slim disease: a new disease in Uganda and its association with HTLV-III infection. Lancet (1985) 4.99
Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med (2001) 4.98
Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS (1988) 4.85
Self-reported antiretroviral therapy in injection drug users. JAMA (1998) 4.75
Chlamydia trachomatis infections in female military recruits. N Engl J Med (1998) 4.68
Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective. Arch Intern Med (2001) 4.68
Azithromycin in control of trachoma. Lancet (1999) 4.32
Characterization of Campylobacter-like organisms isolated from homosexual men. J Infect Dis (1984) 4.23
Spread of HIV infection in married monogamous women in India. JAMA (1997) 4.18
Incident Chlamydia trachomatis infections among inner-city adolescent females. JAMA (1998) 4.12
Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology (1999) 4.11
Multiply antibiotic-resistant Staphylococcus aureus: introduction, transmission, and evolution of nosocomial infection. Ann Intern Med (1982) 3.95
Diagnosis of Chlamydia trachomatis urethral infection in symptomatic and asymptomatic men by testing first-void urine in a ligase chain reaction assay. J Infect Dis (1994) 3.93
Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) (1995) 3.85
Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA (1992) 3.81
A new molluscicide, N-tritylmorpholine. Nature (1966) 3.77
Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med (1997) 3.71
Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis (1999) 3.69
Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 3.68
Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science (1998) 3.60
Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS (2001) 3.56
A randomized, community trial of intensive sexually transmitted disease control for AIDS prevention, Rakai, Uganda. AIDS (1998) 3.54
Performance of the APTIMA Combo 2 assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in female urine and endocervical swab specimens. J Clin Microbiol (2003) 3.50
Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. Am J Epidemiol (1995) 3.44
Multicenter evaluation of the AMPLICOR and automated COBAS AMPLICOR CT/NG tests for detection of Chlamydia trachomatis. J Clin Microbiol (2000) 3.44
HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA (2001) 3.41
Risk factors for HIV infection in people attending clinics for sexually transmitted diseases in India. BMJ (1995) 3.38
HIV incidence and sexually transmitted disease prevalence associated with condom use: a population study in Rakai, Uganda. AIDS (2001) 3.30
Isolation of human lymphotropic herpesviruses from Uganda. Lancet (1987) 3.26
Field testing and comparative evaluation of rapid, visually read screening assays for antibody to human immunodeficiency virus. Lancet (1989) 3.18
Diagnosis of Chlamydia trachomatis infections by direct immunofluorescence staining of genital secretions. A multicenter trial. Ann Intern Med (1984) 3.15
The polymicrobial origin of intestinal infections in homosexual men. N Engl J Med (1983) 3.12
Tuberculosis in household contacts of infectious cases in Kampala, Uganda. Am J Epidemiol (2003) 3.09
Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. JAMA (1998) 3.07
Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. JAMA (1992) 3.07
Chlamydia trachomatis proctitis. N Engl J Med (1981) 3.02
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol (1996) 2.86
Voluntary testing for human immunodeficiency virus (HIV) in a prison population with a high prevalence of HIV. Am J Epidemiol (1994) 2.81
Diagnosis of Trichomonas vaginalis infection by PCR using vaginal swab samples. J Clin Microbiol (1998) 2.81
Multicenter evaluation of AMPLICOR and automated COBAS AMPLICOR CT/NG tests for Neisseria gonorrhoeae. J Clin Microbiol (2000) 2.80
Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics. A cost-effectiveness analysis of three strategies. Ann Intern Med (1998) 2.78
Factors associated with adolescent initiation of injection drug use. Public Health Rep (2001) 2.73
Assessment of neonatal conjunctivitis with a direct immunofluorescent monoclonal antibody stain for Chlamydia. JAMA (1986) 2.69
Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med (2001) 2.68
Infections with Campylobacter jejuni and Campylobacter-like organisms in homosexual men. Ann Intern Med (1984) 2.65
Evidence for high prevalence & rapid transmission of HIV among individuals attending STD clinics in Pune, India. Indian J Med Res (1996) 2.64
Correlates of HIV infection among young adult short-term injection drug users. AIDS (2000) 2.63
NIH conference. Gastrointestinal infections in AIDS. Ann Intern Med (1992) 2.62
Screening women for chlamydia trachomatis in family planning clinics: the cost-effectiveness of DNA amplification assays. Sex Transm Dis (1998) 2.60
The etiology of genital ulcer disease by multiplex polymerase chain reaction and relationship to HIV infection among patients attending sexually transmitted disease clinics in Pune, India. Sex Transm Dis (1999) 2.57
Radiation Therapy Oncology Group: radiosurgery quality assurance guidelines. Int J Radiat Oncol Biol Phys (1993) 2.55
Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol (1997) 2.55
Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun (1996) 2.52
Using social network analysis to study patterns of drug use among urban drug users at high risk for HIV/AIDS. Drug Alcohol Depend (1995) 2.51
Seroreactivity to hepatitis E virus in areas where the disease is not endemic. J Clin Microbiol (1997) 2.48
Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis (2001) 2.47
Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N Engl J Med (1991) 2.46
Acquired immunodeficiency syndrome in a heterosexual population in Zaire. Lancet (1984) 2.43
Trends in HIV-1 prevalence may not reflect trends in incidence in mature epidemics: data from the Rakai population-based cohort, Uganda. AIDS (1997) 2.42
HIV risk factors in three geographic strata of rural Rakai District, Uganda. AIDS (1992) 2.41
Hepatitis B and hepatitis C in emergency department patients. N Engl J Med (1992) 2.39
Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence. AIDS (2000) 2.37